Prognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?

Basit Öğe Kaydı
dc.authorid0000-0002-4632-9501
dc.authorid0009-0003-0923-5148
dc.authorid0000-0002-0853-4096
dc.authorid0000-0002-9883-3398
dc.authorid0000-0002-3386-2075
dc.authorid0009-0009-9381-3409
dc.contributor.authorBeypinar, Ismail
dc.contributor.authorUrvay, Semiha
dc.contributor.authorUrun, Muslih
dc.contributor.authorErcek, Berrak
dc.contributor.authorDemir, Hacer
dc.contributor.authorYildiz, Canan
dc.contributor.authorAraz, Murat
dc.date.accessioned2026-01-24T12:30:52Z
dc.date.available2026-01-24T12:30:52Z
dc.date.issued2025
dc.departmentAlanya Alaaddin Keykubat Üniversitesi
dc.description.abstractBackground Although there are multiple treatment options, oncologists lack appropriate biomarkers for determining the efficacy and toxicity of immunotherapy. In this study, we aimed to use a combination of the clinical parameters of IMDC risk groups at the time of diagnosis to predict the effectiveness of immunotherapy. Methods This multicenter cross-sectional study retrospectively analyzed non-small cell lung cancer (NSCLC) patients receiving nivolumab for the prognostic effects of clinical factors, including the IMDC score. Results Two hundred and five patients were enrolled in this study. There was no favorable group because the TTI was less than 1 year in the entire study group in the IMDC. The IMDC score and IMDC groups showed significant differences in PFS (p < 0.001; p < 0.001, respectively). Intermediate and poor-risk groups had PFS of 8 and 3 months PFS, respectively. The IMDC group showed a significant effect on OS (p = 0.002). The intermediate- and poor-risk groups had 12- and 4-month OS, respectively. The TTI risk factor excluded patient numbers in the favorable, intermediate, and poor risk groups were 47, 129, and 29, respectively, in the revised IMDC group (rIMDC). The prognostic effect of the rIMDC score and groups remained significant (p < 0.001 and p < 0.001, respectively). The classical IMDC had a significant effect on PFS in the multivariate analysis (p = 0.016). Also, rIMDC score in multivariate analysis resulted with significant effect on OS (p = 0.035). Conclusion To date, this is the first study to prove that the IMDC may be a valuable option for predicting both prognosis and treatment efficacy in NSCLC patients receiving especially second or further lines nivolumab treatment.
dc.identifier.doi10.1007/s00228-025-03810-0
dc.identifier.endpage570
dc.identifier.issn0031-6970
dc.identifier.issn1432-1041
dc.identifier.issue4
dc.identifier.pmid39971806
dc.identifier.scopus2-s2.0-85218107879
dc.identifier.scopusqualityQ2
dc.identifier.startpage561
dc.identifier.urihttps://doi.org/10.1007/s00228-025-03810-0
dc.identifier.urihttps://hdl.handle.net/20.500.12868/5501
dc.identifier.volume81
dc.identifier.wosWOS:001426221900001
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherSpringer Heidelberg
dc.relation.ispartofEuropean Journal of Clinical Pharmacology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260121
dc.subjectIMDC
dc.subjectNon-small cell lung cancer
dc.subjectImmunotherapy
dc.subjectNivolumab
dc.subjectPrognostic
dc.subjectBiomarker
dc.titlePrognostic value of IMDC score in non-small cell lung cancer receiving immunotherapy: old dog, new tricks?
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu